

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED

武夷國際藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that it is presently expected that the results of the Group for six months period ended 30 June 2009 as compared to a profit for the six months period ended 30 June 2008 will be affected.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wuyi International Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company and potential investors that having assessed the currently available information, the Group is likely to record a decline in net profit for the six months period ended 30 June 2009 as compared with a net profit for the six months period ended 30 June 2008. The Board considers that the Group’s financial performance has been affected mainly by the following reasons:

1. The adverse macro-economic conditions and substantial downturn of the global financial markets since the second half of 2008, the demand for pharmaceutical products remains unsatisfactory in the first half of 2009, which in turn affected the turnover of the Group in this period; and

2. The Group has incurred an advertising expense of approximately RMB24.0 million for the six months period ended 30 June 2009 under the fulfillment of advertising contact entered in December 2008.

As the Company is still in the process of finalizing its results for the six months period ended 30 June 2009, the information contained in this announcement is a preliminary estimate given by the management of the Group according to the management of the Group. Further details of the Group's performance will be disclosed when the Group's interim results for the six months ended 30 June 2009 are announced.

Despite the lower profit for the six months period ended 30 June 2009, the Board considers that the Group's overall financial position is still healthy and the Board remains positive on the long term prospect of the Group.

Shareholders of the Company and potential investors are advised to exercise caution in dealing in the shares of the Company.

By Order of the Board
Wuyi International Pharmaceutical Company Limited
Lin Ou Wen
Chairman and Chief Executive Officer

Hong Kong, 31 July 2009

As at the date of this announcement, the Board comprises 3 Executive Directors, namely Mr. Lin Ou Wen (Chairman), Mr. Lin Qing Ping and Mr. Xu Chao Hui, 2 Non-executive Directors, namely Mr. Tang Bin and Mr. John Yang Wang, and 3 Independent Non-executive Directors, namely, Mr. Liu Jun, Mr. Lam Yat Cheong and Mr. Du Jian.